Recentin
(cediranib maleate)Phase 3Small molecule
Cediranib maleate is used to treat certain types of cancer, particularly ovarian cancer when used in combination with other chemotherapy drugs. It works by blocking the growth of new blood vessels that tumors need to survive and grow.[1] Recentin is currently being investigated across 6 indications[3], with its most advanced program in Phase 3.[1]
Recentin is one of 57 small molecule programs targeting Fallopian Tube Clear Cell Adenocarcinoma. It is currently in Phase 3.
6
Indications
50
Total Trials
10
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
311 competitors in Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Fludara
SanofiPhase 2
Avastin
RochePhase 2
Beyfortus
BeiGenePhase 2
Imfinzi
AstraZenecaPhase 2
Recentin
NNational Cancer Institute (NCI)
Phase 3
Yervoy
Bristol-Myers SquibbPhase 2
Erbitux
IImclone
Phase 2
Braftovi
PfizerPhase 2
Libtayo
RegeneronPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q1 2027
Phase 2Active, not recruiting
Fallopian Tube Carcinoma
NCT02345265
Phase 3Active, not recruiting
Fallopian Tube Clear Cell Adenocarcinoma
NCT02446600
PreclinicalActive, not recruiting
Fallopian Tube Clear Cell Adenocarcinoma
NCT02502266
Phase 1Active, not recruiting
Metastatic Melanoma
NCT01364051
PreclinicalActive, not recruiting
Epithelioid Mesothelioma
NCT01064648
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer6 trials
Show 3 more trials
Glioblastoma4 trials
Liver Cancer2 trials
Small Cell Lung Cancer2 trials
30 more indications
Breast Cancer2 trials
Kidney Cancer2 trials
Fallopian Tube Carcinoma2 trials
Fallopian Tube Clear Cell Adenocarcinoma2 trials
Patients With Advanced Solid Tumors1 trial
Biliary Cancer1 trial
Metastatic Head and Neck Cancer1 trial
Colorectal Cancer1 trial
Malignant Pleural Mesothelioma1 trial
Endometrial Cancer1 trial
Metastatic Colorectal Cancer1 trial
Malignant Mesothelioma1 trial
Refractory1 trial
Advanced Solid Tumors1 trial
Myelodysplastic Syndrome1 trial
Chronic Lymphocytic Leukemia1 trial
Cervical Cancer1 trial
Thyroid Cancer1 trial
Metastatic Prostate Cancer1 trial
Neurofibromatosis Type 11 trial
Treatment1 trial
Anaplastic Astrocytoma1 trial
Uveal Melanoma1 trial
Recurrent Glioblastoma1 trial
Metastatic Melanoma1 trial
Epithelioid Mesothelioma1 trial
Endometrial Adenocarcinoma1 trial
Fallopian Tube Mucinous Adenocarcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for cediranib maleate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- NNational Cancer Institute (NCI)